Medicine and Dentistry
Heart Failure
85%
Acute Decompensated Heart Failure
41%
Kidney Function
26%
Diuretic Agent
22%
Glomerular Filtration Rate
20%
Ejection Fraction
16%
Biological Marker
14%
Urinary System
13%
Chronic Kidney Disease
11%
Acetazolamide
10%
Hazard Ratio
10%
Cardiology
9%
Loop Diuretic Agent
9%
Left Ventricular Assist Device
9%
Cardiovascular System
8%
Brain Natriuretic Peptide
8%
Heart Left Ventricle Ejection Fraction
8%
Quality of Life
7%
Heart Failure with Preserved Ejection Fraction
7%
Volume Overload
7%
Pathophysiology
7%
Heart Failure with Reduced Ejection Fraction
7%
Placebo
7%
Heart Transplantation
6%
Systolic Heart Failure
6%
Hemodynamic
6%
Creatinine
6%
Natriuresis
6%
Neutrophil Gelatinase Associated Lipocalin
5%
Meta-Analysis
5%
Kidney Injury Molecule 1
5%
Kidney Graft
5%
Amino Terminal Sequence
5%
Transplantation
5%
All Cause Mortality
5%
Assisted Circulation
5%
Atrial Fibrillation
5%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
100%
Acute Heart Failure
48%
Diuretic Agent
24%
Creatinine
13%
Loop Diuretic Agent
13%
Biological Marker
12%
Placebo
12%
Chronic Kidney Failure
12%
Acetazolamide
9%
Neutrophil Gelatinase Associated Lipocalin
8%
Brain Natriuretic Peptide
8%
Angiotensin
8%
Renin
8%
All Cause Mortality
7%
Pathophysiology
7%
Systolic Heart Failure
6%
Heart Failure with Reduced Ejection Fraction
6%
Heart Failure with Preserved Ejection Fraction
6%
Kidney Injury Molecule 1
6%
Atrial Fibrillation
5%
Aldosterone
5%
Empagliflozin
5%
Keyphrases
Heart Failure
31%
Acute Heart Failure
26%
Patients with Heart Failure
20%
Renal Function
15%
Renal Function Improvement
14%
Estimated Glomerular Filtration Rate
13%
Chronic Heart Failure
12%
Heart Failure with Preserved Ejection Fraction (HFpEF)
11%
Clinical Outcomes
10%
Acetazolamide
9%
Acute Decompensated Heart Failure
9%
Heart Failure Patients
8%
Hazard Ratio
8%
Preserved Ejection Fraction
8%
Confidence Interval
8%
Diuretics
7%
Glomerular Filtration Rate
7%
All-cause Mortality
7%
Decongestion
6%
Renal Outcome
6%
Volume Overload
6%
Loop Diuretics
6%
Chronic Kidney Disease
6%
Heart Failure Hospitalization
6%
Placebo
6%
Health-related Quality of Life
6%
Atrial Fibrillation
5%
Reduced Ejection Fraction
5%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
5%
Patients with Chronic Heart Failure
5%
Congestion
5%
Kidney Transplant Recipients
5%
Solid Organ Transplant Recipients
5%
Prognostic Value
5%
Renal Disease
5%
Diuretic Response
5%
